Physician profile
Robert B Shepherd
NPI 1205995438
$2,929.92
in general payments reported to CMS, 2019-2025
17 companies · $935 in 2025
The $935 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.47 · 2022: $457 · 2023: $696 · 2024: $828 · 2025: $935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,458.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $769.96 | 2022-2025 | Spravato |
| Lilly USA, LLC | $572.32 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Exact Sciences Corporation | $187.96 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $172.95 | 2022-2024 | Shingrix, Arexvy |
| Pfizer INC. | $161.01 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.93 | 2021-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $141.76 | 2022-2023 | Breztri, Farxiga |
| Novo Nordisk INC | $134.33 | 2022-2024 | Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $128.31 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Aimmune Therapeutics, INC. | $110.06 | 2024-2025 | Vowst, Zenpep |
| Lundbeck LLC | $94.42 | 2025 | Rexulti |
| Abbott Laboratories | $81.41 | 2022-2025 | Freestyle Libre 3 |
| Ardelyx, INC. | $68.37 | 2024-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $62.36 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.58 | 2025 | Xifaxan |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $20.31 | 2022 | |
| Lucid Diagnostics INC. | $19.88 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Shepherd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.